| All Releases |
|---|
CLINICAL DATA DECLARES FOURTEENTH CONSECUTIVE QUARTERLY CASH DIVIDEND
Apr 19, 2004
|
40.3 KB
|
Bristol-Myers Squibb Medical Imaging and Adenosine Therapeutics Announce Initiation of Phase II Clinical Trials for Novel Pharmacologic Stress Agent
Mar 24, 2004
|
9.2 KB
|
CLINICAL DATA WILL NOT INCREASE OFFER TO MOORE MEDICAL
Mar 3, 2004
|
43.7 KB
|
CLINICAL DATA INCREASES OFFER BY $2 PER SHARE IN CASH
Feb 26, 2004
|
105.8 KB
|
CLINICAL DATA OFFERS TO MERGE WITH MOORE MEDICAL CORP.
Feb 24, 2004
|
104.2 KB
|
CLINICAL DATA REPORTS PROFITABLE THIRD QUARTER
Feb 17, 2004
|
86.3 KB
|
CLINICAL DATA DECLARES THIRTEENTH CONSECUTIVE QUARTERLY CASH DIVIDEND
Jan 16, 2004
|
40.4 KB
|
CLINICAL DATA S-3 OF COMMON STOCK DECLARED EFFECTIVE BY SEC
Jan 13, 2004
|
43.7 KB
|
CLINICAL DATA NAMES GARTH "GUS" GARDNER AS CHIEF OPERATING OFFICER
Jan 5, 2004
|
39.8 KB
|
Adenosine Therapeutics Announces Appointment of William Gray, Vice President of Licensing and Secretary; and Shannon Williams, Vice President of Regulatory Affairs and Clinical Development
Dec 9, 2003
|
9.0 KB
|
Adenosine Therapeutics Wins SBIR Grant to Develop Long Lasting A2A Agonists
Dec 2, 2003
|
7.9 KB
|
Adenosine Therapeutics awarded two patents for the treatment of inflammatory diseases with adenosine A2a agonists
Nov 6, 2003
|
7.8 KB
|
Adenosine Therapeutics awarded SBIR bio-terrorism grant
Oct 30, 2003
|
7.9 KB
|
Adenosine Therapeutics Announces Venture Financing with the Emerging Technology Partners Acquires License to Aptus Pharmaceuticals Adenosine Screening Technology
Sep 9, 2003
|
7.7 KB
|
Adenosine Therapeutics Announces Appointment of Dr. Michael Williams to the Board of Directors
Aug 19, 2002
|
8.5 KB
|
Phase II Grant Approved for Adenosine Therapeutics to Continue Study of A2A Agonists for Adjunct Sepsis Therapy
May 30, 2002
|
8.7 KB
|
NIH Fast Track Grant Awarded for Study of Adenosine Therapeutics' A2A Agonists as Neuroprotectants
Mar 11, 2002
|
8.3 KB
|
Adenosine Therapeutics' Collaborator to Present New Sepsis Study at ICAAC
Sep 17, 2001
|
8.4 KB
|
New Patent Issues for Adenosine Therapeutics’ Family of Potent and Selective Anti-inflammatory A2A Agonists
May 25, 2001
|
8.7 KB
|
Adenosine Therapeutics Licenses Patented Method for Improving Insulin Sensitivity Using A2B Adenosine Receptor Antagonists
May 16, 2001
|
8.9 KB
|
|
